Attovia

formerly Attovia TherapeuticsIPO

Shaping the future of I&I with first-in-class multispecifics

Fremont, United States · Founded 2023 · $255.0M raised

Employees
11–50
Founded
2023
Business Model
B2B
Total Funding
$255.0M
Last Round
$90.0M Series CApr 2025
Rounds
3

About

Attovia Therapeutics is a clinical-stage biopharmaceutical company creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases and oncology. Founded in 2023, the company leverages its proprietary ATTOBODY™ platform — a biparatopic nanobody technology — to develop first-in-class precision biologics designed to address areas of high unmet medical need. Attovia has raised Series A, B, and C financing to advance its pipeline toward the clinic.

Summary

Attovia is a Biotech company based in Fremont, United States, founded in 2023. It has raised $255.0M in total across 3 rounds, most recently a $90.0M Series C round in Apr 2025. Investors include Frazier Life Sciences, Deep Track Capital and Goldman Sachs Alternatives.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

IPOAug 2026
$289.0M

Sign up to see all 4 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Attovia on Indexed.vc
<a href="https://indexed.vc/companies/attovia"><img src="https://indexed.vc/api/badge/company/attovia" alt="Attovia on Indexed.vc" width="260" height="76" /></a>